Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neladenoson bialanate dose-finding Phase II trial in heart failure with preserved ejection fraction
2016-004062-26Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of neladenoson bialanate in heart failure with preserved ejection fraction (HFpEF) and chronic heart failure (CHF) (4 arms), sponsored by Bayer. Primary endpoint: Absolute change from baseline in 6-minute walk distance at 20 weeks. Started Mar 2017; status: completed.
02
Drugs
neladenoson bialanate
03
Conditions
heart failure with preserved ejection fraction (HFpEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2016-004062-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004062-26.